Hereditary Breast and Ovarian Cancer Syndrome Treatment Global Market Report 2024

The hereditary breast and ovarian cancer syndrome treatment market size has grown strongly in recent years. It will grow from $6.28 billion in 2023 to $6.72 billion in 2024 at a compound annual growth rate (CAGR) of 7.1%. The expansion observed in the historical period can be attributed to factors such as heightened awareness and screening practices, supportive government policies, initiatives promoting patient advocacy and empowerment, and collaborative efforts in research.

The hereditary breast and ovarian cancer syndrome treatment market size is expected to see strong growth in the next few years. It will grow to $8.57 billion in 2028 at a compound annual growth rate (CAGR) of 6.3%. The anticipated growth in the forecast period can be attributed to the increasing role of artificial intelligence, broader access to genetic counseling, regulatory approvals for targeted therapies, the development of personalized treatment plans, and international collaborations in research. Key trends in the forecast period encompass the use of gene editing technologies, advancements in immunotherapy, technological progress in oncology, the application of immunotherapy for BRCA-related cancers, and the adoption of comprehensive multidisciplinary care approaches.

The anticipated increase in genetic disorders is set to drive the growth of the hereditary breast and ovarian cancer syndrome treatment market in the coming years. Newborn screening, a post-birth examination for specific health conditions in infants, enables health professionals to identify and address specific needs before any potential health issues arise. This screening could identify infants at a higher risk of developing breast and ovarian cancer, allowing for early preventive measures. In 2022, the Texas Department of State Health Services reported a 4.3% increase in newborn screening specimens received, rising from 729,347 in 2021 to 761,000 in 2022. Of these, approximately 394,000 babies were screened, with 1,130 affected by one of the NBS disorders in 2022. Therefore, the surge in genetic disorders is a key factor propelling the growth of the hereditary breast and ovarian cancer syndrome treatment market.

The rising prevalence of ovarian cancer is expected to further fuel the growth of the hereditary breast and ovarian cancer syndrome treatment market. Ovarian cancer, a malignant tumor in the ovaries, has seen increased prevalence due to factors such as increased longevity, delayed childbearing, and changes in lifestyle. Hereditary Breast and Ovarian Cancer Syndrome (HBOC), a genetic condition elevating the risk of breast, ovarian, and other cancers, is a significant contributor to this trend. According to the World Ovarian Cancer Coalition's February 2022 report, ovarian cancer affected 313,959 women globally in 2020, and this number is projected to rise by 42% to 445,721 between 2020 and 2040. Consequently, the growing prevalence of ovarian cancer is a driving force behind the growth of the hereditary breast and ovarian cancer syndrome treatment market.

The presence of alternative treatment options is expected to pose a challenge to the future expansion of the hereditary breast and ovarian cancer syndrome treatment market. The availability of alternative treatments may lead to price competition, as patients might opt for perceived safer or more effective alternatives. Notably, the cost of genetic testing for BRCA mutations has significantly decreased in recent years, potentially impacting market profitability. Therefore, the existence of alternative treatment options is likely to impede the growth of the hereditary breast and ovarian cancer syndrome treatment market.

Major companies in the hereditary breast and ovarian cancer syndrome treatment market are adopting innovative treatment options, such as comprehensive risk tests, to enhance their services. A comprehensive risk assessment test is a tool designed to identify an individual's risk of developing a disorder or experiencing symptoms of a disease. Genetic Technologies Limited, an Australia-based molecular diagnostics company, launched a groundbreaking comprehensive risk assessment test in February 2023. This test combines gene mutation testing for breast and ovarian cancers, assesses hereditary and non-hereditary risk factors, and calculates the GeneType risk score for both cancers. It targets women over 30 at a higher risk of breast and ovarian cancer in the general population.

In March 2023, Invitae Corporation, a US-based biotechnology company, entered into a partnership with Epic Systems Corporation to streamline the genetic testing process. This collaboration aims to integrate genetic information into standard workflows, facilitating enhanced personalized healthcare delivery within the Epic community. Epic Systems Corporation, a US-based platform provider, plays a crucial role in evaluating a patient's risk for hereditary cancer, including hereditary breast and ovarian cancer syndrome (HBOC).

Major companies operating in the hereditary breast and ovarian cancer syndrome treatment market report are Pfizer Inc., Johnson & Johnson Private Limited, F. Hoffmann-La Roche Ltd., Merck & Co., AbbVie Inc., Bayer AG, Sanofi-Aventis LLC , AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Co. Ltd., Vertex Pharmaceuticals Inc., Mercy Health, Hikma Pharmaceuticals plc, Amneal Pharmaceuticals LLC, Lupin Limited , Seagen Inc., LEO Pharma Inc., LifeLabs Genetics, Natera Inc., Fresenius Kabi AG, Myriad Genetics Inc., Invitae Corporation, Editas Medicine Inc., GenMark Diagnostics Inc., Genentech Inc., CRISPR Therapeutics AG, Advocate Health Care.

North America was the largest region in the hereditary breast and ovarian cancer syndrome treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary breast and ovarian cancer syndrome treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa The countries covered in the hereditary breast and ovarian cancer syndrome treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The hereditary breast and ovarian cancer syndrome treatment market consists of revenues earned by entities by providing services such as genetic testing and counseling, surveillance, screening, prophylactic surgeries, chemoprevention, clinical trials, ongoing monitoring, family testing, and psychosocial support. The market value includes the value of related goods sold by the service provider or included within the service offering. The hereditary breast and ovarian cancer syndrome treatment market also includes sales of lynparza, talazoparib, rucaparib, and niraparib. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The primary treatments for hereditary breast and ovarian cancer syndrome include hormonal therapy, chemoprevention, genetic counseling, medication, and other therapeutic approaches. Hormone replacement therapy, specifically estrogen-based and of a temporary nature, is targeted at alleviating individual acute symptoms in cases of hereditary breast and ovarian cancer (HBOC) syndrome, particularly in individuals with BRCA1 or BRCA2 mutations. Diagnosis involves genetic testing, magnetic resonance imaging (MRI), mammography, and other methods. Medications can be administered through various routes, including oral, parenteral, and others, with delivery facilitated by hospitals, specialty clinics, home care services, and other healthcare providers.

The hereditary breast and ovarian cancer syndrome market research report is one of a series of new reports that provides hereditary breast and ovarian cancer syndrome market statistics, including hereditary breast and ovarian cancer syndrome industry global market size, regional shares, competitors with a hereditary breast and ovarian cancer syndrome market share, detailed hereditary breast and ovarian cancer syndrome market segments, market trends and opportunities, and any further data you may need to thrive in the hereditary breast and ovarian cancer syndrome industry. This hereditary breast and ovarian cancer syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.